Furthermore, disease control by maintenance therapy with rituximab every 3 months is used in patients with follicular lymphoma. LON is a common side effect of rituximab treatment.

Roche’s phase III SUNMO study of Lunsumio & Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma ...

However, the true incidence and mechanisms are not fully understood. LON has been reported in 5–27% of rituximab-treated lymphoma patients.

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can ...

Roche’s lymphoma portfolio is one of the broadest in the industry, providing a unique and much-needed opportunity to combine regimens with different and complementary mechanisms of action.

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

They demonstrated that these LAMM cells specifically impair the therapeutic function of the CAR-T cells against the lymphoma and are therefore contributing to the failure of CAR-T cell therapy.